Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

• Proportion of patients with accelerated or blast phase CML who convert to at least chronic phase CML [ Time Frame: Monthly evaluations ] [ Designated as safety issue: No ]
• Tolerance and toxicity of the combined HHT- imatinib mesylate treatment regimen. [ Time Frame: On going ] [ Designated as safety issue: No ]
• Proportion of patients with chronic phase CML who are in hematologic remission (CHR) or improved cytogentics at study onset [ Time Frame: Monthly evaluations ] [ Designated as safety issue: No ]

• Proportion of patients with accelerated or blast phase CML who convert to at least chronic phase CML
• Tolerance and toxicity of the combined Homoharringtonine and Gleevec treatment regimen
• Proportion of patients with chronic phase CML who achieve complete hematologic remission (CHR) or improved cytogenetics if in CHR at study onset

• Proportion of patients achieving hematologic improvement
• Proportion of patients returning to chronic phase CML
• Response rate of patients with extramedullary disease (EMD)
• Proportion of patients with chronic, accelerated or blast phase CML, respectively, who achieve a hematologic response or cytogenetic response
• Onset of response
• Duration of response
• Survival

This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine may restore a response to Gleevec or the combined treatment may promote a better response than using Gleevec alone.

Every 4 weeks, the study medicine Homoharringtonine will be given by vein daily for 5 days along with continuing daily doses of the approved medicine Gleevec taken by mouth. The safety and effectiveness of this combined treatment in CML patients will be studied. Patients who do not achieve a meaningful hematologic or cytogenetic response after 4 cycles or less will be discontinued. Otherwise, patients may continue additional cycles of this combined treatment for a maximum of 12 cycles.

• Myeloid Leukemia, Chronic
• Myeloid Leukemia, Chronic, Accelerated-Phase
• Blast Phase
• Myeloid Leukemia, Chronic, Chronic-Phase

Inclusion Criteria:

• Male or female patients 16 years or older
• Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) in either chronic, accelerated or blast phase
• Patients with chronic phase CML will be either refractory (failed to achieve hematologic or cytogenetic response) or resistant (responded initially but subsequently lost hematologic or cytogenetic response) to prior imatinib mesylate therapy. Failure to achieve cytogenetic response is defined as follows: no cytogenetic response after 3 months of therapy with imatinib mesylate, no major cytogenetic response at 12 months of therapy, loss of complete cytogenetic response documented twice, or loss of major cytogenetic response at least once.
• Patients with accelerated or blast phase may be newly diagnosed and previously untreated or if previously treated with imatinib mesylate, will be refractory or resistant to this agent or have failed to achieve at least a complete hematologic or cytogenetic response to treatment, as previously defined.
• Patients in accelerated phase will meet one or more of the following criteria: greater than or equal to 15% through less than 30% blasts in peripheral blood or bone marrow, greater than or equal to 30% blasts + promyelocytes in peripheral blood or bone marrow, greater than or equal to 20% basophils in peripheral blood, platelet count less than 100 x 1000000000/L unrelated to therapy or clonal evolution.
• CML in blast phase will be defined as greater than or equal to 30% blasts in the bone marrow or presence of extramedullary disease
• Patients must have completed all previous anti-leukemic therapy for at least 2 weeks, except as noted, and have fully recovered from side effects of a previous therapy, unless disease progression necessitates early therapy. Patients may receive leukapheresis, hydroxyurea and anagrelide for up to 24 hours prior to start of study treatment. Patients receiving imatinib mesylate may continue to receive it uninterrupted, except for a 3-day window at treatment cycle 1.
• Bilirubin less than or equal to 2 times the upper limit of normal (ULN); ALT less than or equal to 3 times ULN; Creatinine less than or equal to 1.5 times ULN
• ECOG performance status 0 - 2
• Be able to comply with the requirements of the entire study
• Be able and willing to provide written informed consent prior to any study related procedure
• Patients and their partners must use an effective contraceptive during the study dosing period. The following are considered effective contraceptives: oral contraceptive pill, condom, diaphragm plus spermicide, abstinence, patient or partner surgically sterile, patient or partner more than 2 years post-menopausal, or injectable or implantable agent/device.

Exclusion Criteria:

• New York Heart Association (NYHA) Class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension or congestive heart failure
• Myocardial infarction in the previous 12 weeks
• Other intercurrent illness which would preclude study conduct and assessment, including but not limited to another active malignancy, uncontrolled and active infection, positive HIV or HTLV I/II status
• Pregnant or lactating
• Any medical or psychiatric condition which may compromise the ability to give written informed consent or to comply with the study protocol